摘要
原发性胆汁性胆管炎是自身免疫性肝病中的一种类型,约有1/3的患者可长期无任何临床表现,在其发病率逐渐上升的当下,通过治疗改善患者预后、提高患者生存率尤为重要。药物治疗是临床工作中最为常用的方法,目前获批的一线用药仅为熊去氧胆酸,关于奥贝胆酸、贝特类等二线药物疗效的研究取得了较多新进展,本文对目前原发性胆汁性胆管炎药物治疗进行介绍总结,旨在为临床治疗提供思路。
Primary biliary cholangitis is a type of autoimmune liver disease.About 1/3 of patients may have no clinical manifestations for a long time.When the incidence rate is gradually rising,it is particularly important to improve the prognosis and survival rate of patients through treatment.Medical management is the most commonly used method in clinical work.At present,the only the first-line treatment approved is Urodeoxycholic acid.More new progress has been made in the research on the efficacy of the second-line medications such as Obeticholic acid and Bates.This article introduced and summarized the current medical management about primary biliary cholangitis in order to provide ideas for clinical treatment.
作者
刘斯琪
斯庆图娜拉
LIU Siqi;Siqingtunala(Inner Mongolia Medical University,Hohhot 010100;Department of Gastroenterology,Ordos Central Hospital,Affiliated Ordos Clinical College of Inner Mongolia Medical University,China)
出处
《胃肠病学和肝病学杂志》
CAS
2023年第5期579-583,共5页
Chinese Journal of Gastroenterology and Hepatology
基金
内蒙古医科大学科技百万工程联合项目(YKD2018KJBW(LH)086)。
